Identification of High-risk Factors As Indicators for Adjuvant Therapy in Stage II Colon Cancer Patients Treated at a Single Institution

Overview

Journal Oncol Lett

Specialty Oncology

Date 2013 Oct 19

PMID 24137386

Citations 7

Authors

Keizo Yamaguchi

Yutaka Ogata

Yoshito Akagi

Kazuo Shirouzu

Affiliations

Soon will be listed here.

Abstract

Although post-operative adjuvant chemotherapy (ACT) is only recommended for patients with stage II colon cancer who are at a high risk of recurrence, the definition of high risk remains unclear. The present study aimed to identify the risk factors for recurrence, which may also be indicators for adjuvant therapy, using a retrospective analysis of clinicopathological data obtained from stage II colon cancer patients who had undergone a curative resection. The present study also investigated the effects of ACT in patients who displayed the risk factors for recurrence. Univariate and multivariate analyses of the data collected from 377 stage II colon cancer patients, treated at Kurume University Hospital (Fukuoka, Japan) between 1982 and 2005, was conducted in order to determine and compare the risk factors for recurrence between the 163 patients who had undergone adjuvant therapy and the 214 patients who had not undergone adjuvant therapy. The risk factors for recurrence in patients who had not undergone adjuvant therapy were a serum carcinoembryonic antigen (CEA) level that was twice the cut-off value and pre-operative bowel obstruction. Adjuvant therapy provided no benefit to patients who presented with neither risk factor, but significantly decreased the recurrence rate in patients presenting with one or both risk factors. Based on these findings, serum CEA levels of twice the cut-off value and pre-operative bowel obstruction were proposed as indicators in the assessment for adjuvant chemotherapy following a curative resection for stage II colon cancer. These results warrant further clinical study of ACT in patients with one or both risk factors.

Citing Articles

A nomogram based on pretreatment levels of serum bilirubin and total bile acid levels predicts survival in colorectal cancer patients.

Cao Y, Deng S, Yan L, Gu J, Yang J, Yang M BMC Cancer. 2021; 21(1):85.

PMID: 33478423 PMC: 7818769. DOI: 10.1186/s12885-021-07805-9.

Colorectal obstruction is a potential prognostic factor for stage II colorectal cancer.

Okuda Y, Shimura T, Yamada T, Hirata Y, Yamaguchi R, Sakamoto E Int J Clin Oncol. 2018; 23(6):1101-1111.

PMID: 29948240 DOI: 10.1007/s10147-018-1307-2.

Extramural Venous Invasion as Prognostic Factor of Recurrence in Stage 1 and 2 Colon Cancer.

van Eeghen E, Flens M, Mulder M, Loffeld R Gastroenterol Res Pract. 2018; 2017:1598670.

PMID: 29317863 PMC: 5727620. DOI: 10.1155/2017/1598670.

Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with stage III and IV colorectal cancer.

Kim J, Lee J, Kim H, Wook Lee J, Jung S, Jung K World J Gastroenterol. 2017; 23(3):505-515.

PMID: 28210087 PMC: 5291856. DOI: 10.3748/wjg.v23.i3.505.

Knockdown of Hypoxia-Inducible Factor 1α Improved the Efficacy of Low-Dose Metronomic Chemotherapy of Paclitaxel in Human Colon Cancer Xenografts.

Zhang M, Chen C, Su F, Huang Z, Li X, Li X Technol Cancer Res Treat. 2016; 16(5):609-619.

PMID: 27573201 PMC: 5665152. DOI: 10.1177/1533034616665720.

References

Wichmann M, Muller C, Hornung H, Lau-Werner U, Schildberg F . Gender differences in long-term survival of patients with colorectal cancer. Br J Surg. 2001; 88(8):1092-8. DOI: 10.1046/j.0007-1323.2001.01819.x. View

Shirouzu K, Isomoto H, Kakegawa T, Morimatsu M . A prospective clinicopathologic study of venous invasion in colorectal cancer. Am J Surg. 1991; 162(3):216-22. DOI: 10.1016/0002-9610(91)90073-m. View

Gold P, Freedman S . DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES. J Exp Med. 1965; 121:439-62. PMC: 2137957. DOI: 10.1084/jem.121.3.439. View

Sener S, Imperato J, CHMIEL J, Fremgen A, Sylvester J . The use of cancer registry data to study preoperative carcinoembryonic antigen level as an indicator of survival in colorectal cancer. CA Cancer J Clin. 1989; 39(1):50-7. DOI: 10.3322/canjclin.39.1.50. View

Schrag D, Rifas-Shiman S, Saltz L, Bach P, Begg C . Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002; 20(19):3999-4005. DOI: 10.1200/JCO.2002.11.084. View

McArdle C, McMillan D, Hole D . Male gender adversely affects survival following surgery for colorectal cancer. Br J Surg. 2003; 90(6):711-5. DOI: 10.1002/bjs.4098. View

Harrison L, Guillem J, Paty P, Cohen A . Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg. 1997; 185(1):55-9. DOI: 10.1016/s1072-7515(97)00012-4. View

Chou C, Chang S, Lin T, Chen W, Jiang J, Wang H . Differences in clinicopathological characteristics of colorectal cancer between younger and elderly patients: an analysis of 322 patients from a single institution. Am J Surg. 2011; 202(5):574-82. DOI: 10.1016/j.amjsurg.2010.10.014. View

Ogata Y, Murakami H, Sasatomi T, Ishibashi N, Mori S, Ushijima M . Elevated preoperative serum carcinoembrionic antigen level may be an effective indicator for needing adjuvant chemotherapy after potentially curative resection of stage II colon cancer. J Surg Oncol. 2008; 99(1):65-70. DOI: 10.1002/jso.21161. View

10.

. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol. 1999; 17(5):1356-63. View

11.

Labianca R, Nordlinger B, Beretta G, Brouquet A, Cervantes A . Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v70-7. DOI: 10.1093/annonc/mdq168. View

12.

Kobayashi H, Mochizuki H, Sugihara K, Morita T, Kotake K, Teramoto T . Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. Surgery. 2006; 141(1):67-75. DOI: 10.1016/j.surg.2006.07.020. View

13.

Shirouzu K, Isomoto H, Morodomi T, Kakegawa T . Carcinomatous lymphatic permeation. Prognostic significance in patients with rectal carcinoma--a long term prospective study. Cancer. 1995; 75(1):4-10. DOI: 10.1002/1097-0142(19950101)75:1<4::aid-cncr2820750103>3.0.co;2-q. View

14.

Locker G, Hamilton S, Harris J, Jessup J, Kemeny N, Macdonald J . ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006; 24(33):5313-27. DOI: 10.1200/JCO.2006.08.2644. View

15.

MOERTEL C, Fleming T, Macdonald J, Haller D, Laurie J, Tangen C . Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol. 1995; 13(12):2936-43. DOI: 10.1200/JCO.1995.13.12.2936. View

16.

Wagner H, Toth C, Steele Jr G, Thomas P . Metastatic potential of human colon cancer cell lines: relationship to cellular differentiation and carcinoembryonic antigen production. Clin Exp Metastasis. 1992; 10(1):25-31. DOI: 10.1007/BF00163573. View

17.

Chin C, Wang J, Changchien C, Huang W, Tang R . Carcinoma obstruction of the proximal colon cancer and long-term prognosis--obstruction is a predictor of worse outcome in TNM stage II tumor. Int J Colorectal Dis. 2010; 25(7):817-22. DOI: 10.1007/s00384-010-0904-y. View

18.

Onate-Ocana L, Montesdeoca R, Lopez-Graniel C, Aiello-Crocifoglio V, Mondragon-Sanchez R, Cortina-Borja M . Identification of patients with high-risk lymph node-negative colorectal cancer and potential benefit from adjuvant chemotherapy. Jpn J Clin Oncol. 2004; 34(6):323-8. DOI: 10.1093/jjco/hyh054. View

19.

Burdy G, Panis Y, Alves A, Nemeth J, Lavergne-Slove A, Valleur P . Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum. 2001; 44(11):1682-8. DOI: 10.1007/BF02234390. View

20.

Van Cutsem E, Oliveira J . Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol. 2008; 19 Suppl 2:ii29-30. DOI: 10.1093/annonc/mdn077. View